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ABSTRACT

Objective: This research examined the contributions of terpenes (volatile oil) and
cannabinoids in cannabis mediated analgesia in rats.

Methods: In experiment 1, separate groups of rats received IP administration of either
vehicle, 5, 10, or 15 mg/kg cannabis extract, one of three concentrations of volatile oil
alone in these cannabis extracts, one of three concentrations of these extracts with volatile
oils removed, 2.5, 5, or 7.5 mg/kg Δ9-THC, or 10 or 18 mg/kg morphine 30 m before
hotplate and tail-flick tests of thermal nociception. One week later, separate groups of
rats received a second administration of these test articles IP 30 m before testing in the
acetic acid writhing test of inflammatory nociception.

Results: Both tail-flick and hotplate latencies were longer than controls for all drug
groups/doses except the isolated volatile oil groups. The 15 mg/kg dose of the cannabis
extract and 7.5mg/kg Δ9 -THC group showed analgesic effects similar to the 18 mg/kg
morphine group. In the inflammatory nociceptive assay, all drug groups/doses showed
decreased writhes compared to the control except the isolated volatile oil groups.

Conclusions: These tests revealed that terpenes do not significantly contribute to the
analgesic action of cannabis extracts. Further, these tests revealed that THC alone
produced robust analgesia equivalent to the whole cannabis extract. This leads to the
conclusion that THC alone mediates these analgesic actions of cannabis extracts and
other components do not significantly affect the analgesic activity of the extract.
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INTRODUCTION
For centuries, natural products have been used all over the world to treat various
types of ailments. From as early as 2600 B.C. in Mesopotamia, people used Cypress and
Myrrh naturally found in the environment to treat anything from coughs to infection
(Dias et al., 2012). Though from China to Egypt these natural products have been used
and documented in ancient texts, very few have been tested to determine if they are
biologically active (Fabricant et al., 2001). Although some natural products are
commonly used today, like salicin, which is used to synthesize aspirin (Dias et al., 2012),
there is still a wide array of natural products that have not been assessed let alone
considered for scientific value. This untapped potential could be the future of medicine,
and in fact, has been the subject of much interest in the last few decades. As tools for
chemical analysis and understanding of biological processes increases, so too does the
understanding of natural products and how they can be used in medicine. With current
prescription drugs becoming a cause for concern, like the opioid epidemic the United
States is facing (Murthy, 2016), researchers are turning towards these natural products to
find alternative treatments. One natural product that has gained huge interest in the last
decade for its medicinal potential is Cannabis.
Cannabis, commonly known as marijuana, can be cultivated from different
varieties of the plant, Cannabis sativa such as C. sativa varieties sativa, C. sativa
varieties indica and C. sativa varieties ruderalis. The two have very different properties,
the main difference being that C. Sativa has a higher ratio of CBD to THC, while C.
Indica has a higher ratio of THC to CBD (Pearce et al., 2014). Throughout many
8

centuries, cannabis has been used by cultures for spiritual and recreational purposes. As
early as 2 A.D., Chinese literature, specifically the Book of Odes, notes that the use of
cannabis can connect one to the spirits and bring enlightenment (Warf, 2014). In
Hinduism, cannabis was used in many religious ceremonies, specifically to honor the god
Shiva (Warf, 2014). Hemp, non-psychoactive cannabis, was even used to create the robe
of the Hebrew King Solomon (Warf, 2014). While having many spiritual applications in
history, cannabis has also been used in recent decades, becoming a popular vice of
choice. In the United States alone, cannabis has been legalized for recreational use, to
reach feelings of “high” or euphoria, in 8 states (Gourdet et al., 2017). Although used for
spiritual and recreational purposes, cannabis also has many real medicinal applications.
Such uses are to relieve symptoms of epilepsy, to stimulate appetite, and to relieve nausea
associated with chemotherapy treatment (Hofmann et al., 2013). One of the most
promising of these applications of cannabis has been as a pain reliever and antiinflammatory drug.
Since 2900 B.C., the Chinese have used cannabis to treat pain. This analgesic
property of cannabis has been confirmed as early as 2001 in a study on capsaicin-evoked
pain in rats by Johanek et al. and in 2007, a study by Wallace et al. found dose-dependent
analgesia of smoked cannabis in healthy human adults. These studies, among others,
have prompted 29 states in the U.S. to begin legalizing the plant for its medicinal usage.
Cannabis has been tested as a method to treat pain because of the manner in which it acts
in the brain. In the body, peripheral nerves detect sensations of pain (Mack et al., 2001)
and in these same areas, there are also cannabinoid receptors (Lynch, 2006).
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Cannabinoids bind to inherent endocannabinoid receptors in the human nervous
system (Noonan, 2015). They inhibit cellular processes by altering “neurotransmission
through CB1 receptors by inhibition of P/Q-type Ca2+ channels and adenyl cyclase and
by activation of K+ channels and mitogen-activated protein kinase” (Walker et al., 2002).
CB2 receptors also promote inhibition, but they act through adenyl cyclase and mitogen
activated protein kinase alone (Walker et al., 2002). The cellular inhibition brought on by
cannabinoid binding to either CB1 receptors in the central nervous system or CB2
receptors in the immune system “modulate neural conduction of pain signals by
mitigating sensitization and inﬂammation” (Hill et al., 2017). These combined effects
inhibit the sensation of pain. Along with blocking pain, cannabinoids treat pain so
robustly because they produce euphoric and anti-inflammatory properties (Greydanus,
2013). In the 38 published clinical trials involving cannabinoid therapies, over 70% of
patients reported positive outcomes with usage for pain treatment (Kennedy, 2014). Δ9Tetrahydrocannabinol alone has also been shown to have these similar analgesic effects.
Δ9-Tetrahydrocannabinol, also known as THC or Δ9-THC, is the main
psychoactive constituent of cannabis. It is the most potent constituent in the plant
material (Vale, 2007). THC has these effects on the body by enhancing “dopaminergic
neurotransmission in brain regions known to be implicated in psychosis” (Vale, 2007).
However, recent studies have shown THC issued as an analgesic, appetite stimulant, and
anxiety reliever (Repka et al., 2006), suggesting that THC interacts in multiple pathways.
Though THC has been isolated as separate component, the whole cannabis plant,
including all constituents, has been shown to be an effective treatment for neuropathic
pain. One drug, Sativex®, has successfully done just so. Sativex® is an oral mucosa
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spray of whole-plant cannabis extract, which contains cannabinoids, THC, and
cannabidiol, CBD (Nurmikko et al., 2007). A clinical study in 2007 by Nurmikko et al.
found that Sativex® was an effective treatment for peripheral neuropathic pain.
Considering then that the plant as a whole can be an effective treatment, researchers are
now interested to see if it is one of these cannabinoids, besides THC or CBD, which also
contribute to the overall efficacy of cannabis for analgesia.
There has been extensive research to show how cannabinoids are direct agonists,
which elevate the endocannabinoid function through fatty-acid amide hydrolase
inhibition to produce analgesia (Suplita et al., 2005). However, the known cannabinoids,
such as THC and CBD, may not be the only contributors to the overall efficacy of
cannabis. There are still unknown components of the plant as well as known components
whose functions and interactions are unknown. Not only are these constituents not clearly
documented, but there is also uncertainty whether these have any effect on the analgesic
action of the plant. As of 2005, there were already 413 of these constituents discovered,
which belong to different classes of compounds (ElSohly et al., 2005). In 2017, ElSohly
et al. reported 565 compounds from Cannabis (ElSohly et al, 2017). As the plant has been
researched more over the last decade, more of these constituents have been found, yet the
activity of the majority of these are unknown. Another effect that these constituents can
have on the overall activity of the cannabis plant is the chemical interactions that they
have with each other (ElSohly et al., 2005). These factors must be considered for
cannabis, as a whole, to be understood.
One class of these constituents whose properties are unknown, yet the topic of
current discussion, are the terpenes. Terpenes are the major components of the volatile oil
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of plants and occur widely in nature (Paduch et al., 2007). They are a class of
hydrocarbons and oxygenated hydrocarbons found in the resin of plants that act as natural
attractants or repellents (Paduch et al., 2007), which give off the characteristic aroma.
Terpenes are biosynthesized from isoprene units at their most basic form. Most terpenes
in volatile oils are monoterpenes (2 isoprene units) and sesquiterpenes (3 isoprene units)
but rarely diterpenes (4 isoprene units). There are many terpenes known to be useful to
modern medicine, such as d-limonene which has been shown to help promote apoptosis
of cancerous cells in the body (Paduch et al., 2007). However, what remains unknown is
how the terpenes of cannabis can play a role in its medicinal value. There has been
speculation that terpenes are responsible for some of the analgesic properties of the plant,
yet this has yet to be tested. Though, there have been in vitro studies that found that some
of the components of the cannabis volatile oils have binding affinity to CB1 and CB2
receptors (Mehmedic et al., 2014), there have been no in vivo studies on their specific
analgesic effects. In short, just because the volatile oils can bind the CB1 and CB2
receptors, this is not direct evidence of a correlation with the inhibition of pain when
these receptors are activated.
This study aims to determine the contribution of terpenes in mediated cannabis
extract by evaluating the plant extract with and without terpenes, isolated terpenes, and
isolated THC across a battery of nociceptive assays, including two thermal pain assays
and one inflammatory pain assay.
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METHODS
Chemical Preparations
Four products were prepared from high potency Cannabis sativa (THC rich plant)
for this study. These four drugs were the cannabis extract heated under reflux, volatile
oil, extract without volatile oil, and the major cannabinoid, Δ9 -THC. To make the total
extract, the dried powdered plant material was extracted by maceration in hexanes for 17
hours. The hexanes solution was drained and evaporated under vacuum to give dried
extract. In order to prepare the first group (total extract under reflux), a portion of the
extract was heated with 500 mL of distilled water under reflux for 3 hours then
dichloromethane (DCM), a heavy solvent was added to a separating funnel where the
extract separated from the water. Anhydrous sodium sulfate was used to dry the DCM
extract. The solvent was then filtered out, and the solution was evaporated under vacuum
using a rotatory evaporator to get rid of DCM. After this process, the extract was further
dried via a pressure vacuum for 15 minutes to make sure that all solvent was out of the
product and we were left with extract under reflux (group 1). This reflux step was done
to decarboxylate the extract on hand (in order to convert all the cannabinoid acids into
natural ones) and to subject the extract to the same conditions to be used to remove the
volatile oil (terpenes) from the extract for pharmacological activity comparison between
extract with terpenes versus extract without terpenes.
The next drug group was the extract without volatile oil. The volatile oil isolated
from the extract will be administered to group 3. To do this, the extract is hydrodistilled
where the volatile oil, or terpenes, evaporate at a low boiling point and are carried by the
13

steam under distillation conditions. The steam (carrying the terpenes) is allowed to
condense and the volatile oil distilled from the extract is collected using a volatile oil
preparation apparatus. Fifteen grams of the total cannabis extract and 500 mL of water
were hydrodistilled for three hours. Just like the extract under reflux, after the
hydrodistillation, the extract without volatile oil was separated from water using
methylene chloride via a separatory funnel. Anhydrous sodium sulfate was used to dry
the extract, the sodium sulfate was then filtered out and washed again with methylene
chloride. The final extract without volatile oil evaporated till dryness under reduced
pressure. The DCM extract was further placed under vacuum to ensure complete
evaporation of any solvent. The remaining product was the extract without the volatile oil
(group 2).
The steam condensed product collected from the hydrodistillation process was a
mixture of the volatile oil and water. In order to separate the water out from the volatile
oil, the mixture was frozen. Since water has a higher freezing point than the volatile oil,
the oil was drained off once the water froze. The drained product was the volatile oil
(group 3). We tested the volatile oil via gas chromatography to make sure than there is
no THC left in the solution after this process.
The final drug group (Δ9 -THC) was provide by Coy Waller lab. (Dr. ElSohly).
The preparation of Δ9 -THC in brief:
The high potency extract (total extract) was subjected to thin film distillation
using POPE® 2`` still under specified rotation, flow rate and temperature. Then the
distillate was chemically derivatized and purified by chromatography to obtain pure Δ9 –
THC (the method of distillation and purification has been filed as a patent).
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In Vivo Screening
i.

Apparatus
For the hot plate assay, Harvard Apparatus, Model #52-8570 measured
thermal nociception. Animals were confined to the heated plate with an open top
acrylic enclosure. A foot switch was used to start and stop a timer, which
measured the time (seconds) that the animal remained on the plate. The hotplate
was set at 53.9 degrees Celsius.
For the tail flick assay, Columbus Instruments, Model #0104-300M measured
thermal nociception. The animals were inserted into a small chamber to confine
them and their tails were placed in the apparatus’ groove, below which there was
a heat lamp that was turned on by a button on the front of the apparatus. When the
animal flicked its tail away from the light stimulus, the apparatus automatically
turns off, and the latency is displayed on the apparatus’ timer. The intensity of the
light was adjusted to yield a baseline latency around 5 seconds in control animals.
For the acetic acid writhing assay, 4 chambers with open tops were placed on
a solid counter to confine animals for the duration of the observation. The boxes
measured 42 cm x 20 cm x 21 cm, allowing enough room in the chambers for
animals to move freely. The sides of the chambers were solid so animals could
not see each other during the observation period.

ii.

Procedure
Male Sprague Dawley rats of 200 grams were selected for this study. The
rats were housed two to a cage. They were fed a diet of pellet food and water.
Their cages were cleaned twice a week. The rats were randomly assigned to drug
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groups using a random number generator. There were on average 12 animals in
each drug group. The rats were broken down into cohorts and tested subsequent
weeks in the same pattern to eliminate potential confounding variables. A cohort
of rats arrived on day one and were handled twice a day for five days. On the
sixth day, rats were weighed and then injected intraperitoneally (IP), with the
assigned drug group delivered in a volume of 1 mL/kg. The injectors nor testers
knew which drug was being injected as a coded system was used to eliminate
potential experimental bias. Thirty minutes later the rats were tested with a
hotplate and then immediately with the tail flick apparatus.
The hotplate assay was a measure of analgesia. When a rat motioned to
lick its paw, it was removed from the hot plate. If no response was monitored
after 35 seconds, the rat was removed from the hotplate and a latency of 35
seconds was recorded as full analgesia. The more robust analgesia the given drug
produced, the longer the rat remained on the hotplate, or a greater latency was
measured.
The tail flick assay was another measure of analgesia. The rat was placed
in a restraint chamber and its tail was laid flat on the device. When the machine
was turned on, a light projected onto the rats’ tail. When the rat made a tail flick,
or distinct movement of the tail away from the stimulus, the test ended and the
latency was measured. If no tail flick was produced after 20 seconds, the light was
turned off and a latency of 20 seconds was recorded as full analgesia. Like the hot
plate test, the more robust analgesia a drug produced, the longer the latency.
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After the rats were tested on day 6, they were brought back to their
housing. They were handled once a day for six more days. On the 14th day, the
rats were weighed and injected IP again with the drug group they had been
assigned, delivered in a volume of 1 mL/kg. Thirty minutes later, the rats were
injected IP with a 0.4% acetic acid solution delivered in a volume of 10 mL/kg
and placed in the observation chambers. The number of times the rats writhed, or
stretched their bodies out forcibly, were tallied. This test measured how well the
drug groups produced anti-inflammatory properties. Unlike the other tests, the
more the drug produced effects, the less the animals writhed.
iii.

Treatment Groups
The four drug groups (extract under reflux, extract without volatile oil,
volatile oil, and THC) were each tested in three dosages. The extract under reflux
was tested at 5.0 mg/kg, 10.0 mg/kg, and 15.0 mg/kg. The extract without volatile
oil and the volatile oil were tested at the amount of each component that would be
found in 5.0 mg/kg of total extract, 10 mg/kg of total extract, and 15.0 mg/kg of
total extract. The THC was tested at 2.5 mg/kg, 5.0 mg/kg, and 7.5 mg/kg. These
groups were also compared to the vehicle in which they were dissolved, which
was 10 % cremaphor, 10% ethanol, and 80% water.
For the tail flick and hotplate tests, these experimental drugs were also
compared to the “gold standard” for analgesia. This positive control was
morphine, tested at 10 mg/kg and 18 mg/kg dosages. Since the morphine was
dissolved in saline, we also tested saline as a vehicle in these two assays.
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The day after the abdominal writhing tests were completed, the animals
were euthanized. This was done a day after testing so that the acetic acid would
not interfere with the Euthasol to ensure that the animals were handled as
humanly as possible.
Statistical Analysis
Data were analyzed using SPSS software. For each assay, one-way ANOVAs
were used to identify treatment effects followed by SNK procedures to identify group
differences. Saline and vehicle treatment groups for both tail flick and hotplate data were
condensed as there was no significant difference in latencies between the two vehicles.
For the acetic acid writhing data, only the vehicle was used as a negative control. In this
assay, it is not uncommon for 15-20 % of animals to be non-responders (see Collier, 1998
for further details). Indeed, 2 rats in the vehicle group did not respond to the acetic acid
administration. These observations prompted us to remove 2 non-responders each
treatment group that contained non-responders. This amounted to 9 out of the 13
conditions tested.
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RESULTS

Hotplate Latency
Latencies from the hotplate assay are summarized in Figure 1. For the vehicle
group, average hotplate latencies were around 10 seconds. As before, the 5.0, 10.0, and
15.0 mg/kg doses of volatile oil were not statistically different from the control. The
hotplate assay revealed increased latency than control for all treatments besides the
volatile oil groups. Consistent with these findings, an one-way ANOVA of hotplate data
revealed a significant main effect for treatment groups, F (14,161)= 10.54, p<0.0001.
SNK procedures identified several homogenous subsets. It revealed increased latency
parallel to increased doses of cannabinoid extracts, both with and without the volatile oil,
and pure THC. The latency of these groups increased as the dosage of drug increased,
and the responses became significantly more different from the vehicle.

Tail Flick Latency
Latencies from the tail flick assay are summarized in Figure 2. In the vehicle
group, latencies averaged around 5 seconds. The 5 mg/kg and 15 mg/kg doses of the
volatile oil group did not statistically differ from the vehicle group. Consistent with these
findings, an one-way ANOVA revealed a significant main effect for treatment groups,
F(14,165)= 9.77, p<0.0001. SNK procedures identified several homogenous subsets. As
with the hotplate assay, the test revealed increased tail flick latency than control for all
drug groups other than the volatile oil groups. It also revealed increased tail flick
19

latencies with 15 mg/kg extract without volatile oil, 15 mg/kg full extract, and the 7.5
mg/kg THC. The latency of all treatments besides volatile oil increased as the dosage of
drug increased.

Acidic Acid Writhing
Writhes from the acetic acid assay are summarized in Figure 3. For the vehicle
group, average writhes were around 15.75 writhes per 30 minute observation. Every
treatment group, besides volatile oil, showed decreased writhes from the vehicle group.
Consistent with these findings, an one-way ANOVA of acetic acid writhing data revealed
a significant main effect for treatment groups F (15,102)= 6.133, p<0.001. SNK
procedures revealed significant decreased average writhes from the vehicle group for
each treatment group besides 2.5 mg/kg THC and 5.0, 10.0, and 15.0 mg/kg doses of
volatile oil. Further, for the 10 mg/kg dosage of volatile oil, there was a significant
increase in average writhes from the vehicle group.
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Figure 1: Hotplate latency: This is a representation of average hotplate latencies (in
seconds) as a function of drug groups. The treatment groups are compared to the vehicle
and the similarities between groups are denoted by the letters above the data bars.
Concentration equivalent is the concentration of oils or extract without oils equivalent to
that found in the full extract.
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Figure 2: Tail Flick Latency: This is a representation of average tail flick latencies (in
seconds) as a function of drug groups. The treatment groups are compared to the vehicle
and the similarities between groups are denoted by the letters above the data bars.
Concentration equivalent is the concentration of oils or extract without oils equivalent to
that found in the full extract.
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Figure 3. Acetic Acid Writhing: This is a representation of average abdominal writhes
as a function of drug groups. A star above the data bar represents significant difference
from the reference group, in this case cremaphor. Concentration equivalent is the
concentration of oils or extract without oils equivalent to that found in the full extract.
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DISCUSSION
This study sought to determine whether volatile oils (terpenes) and other cannabis
constituents contribute to cannabis mediated analgesia. To answer this question, we
prepared four cannabinoid products that included the full extract, isolated THC, extract
without volatile oils, and pure volatile oils and tested these products at three different
doses for each. We evaluated these products on three nociceptive assays: tail flick
apparatus and hotplate apparatus, both thermal nociception screens, as well as acetic acid
writhing, which measured inflammatory nociception.
On both tests of thermal nociception, the vehicle animals should produce the
shortest latencies (time the animal remained on the hotplate or with their tail under the
light), since there is no drug mediating the animal’s response to pain. In contrast, animals
from a treatment group with a robust analgesic effect will produce longer latency. In the
tail flick test of thermal nociception, the isolated THC treatment groups showed the
longest latencies suggesting these treatments produced robust analgesia. The extract
without volatile oil and the full extract produced long latencies as well, suggesting these
treatments also produced robust analgesia. Since the isolated THC produced equivalent
analgesia to the full extract, it can be suggested that THC alone is responsible for the
analgesic actions of cannabis or that other constituents including the terpenes have no
significant effect on the analgesic activity of cannabis. Furthermore, these tests revealed a
dose-dependent response in these three groups. The highest dosage in all three of these
groups produced robust analgesia equivalent to the 18.0 mg/kg dosage of morphine, the
gold standard for pain treatment. Meanwhile, the latency of the volatile oil treatment
24

groups did not differ statistically from the latency of the vehicle treatment group. This
suggests that volatile oils do not contribute to the analgesic action of cannabis. Since the
extract without volatile oil treatment group did not differ statistically from the full extract
treatment, it is further suggested that volatile oils do not play a role in the analgesic
action of cannabis. The hotplate test of thermal nociception also produced robust
analgesia in isolated THC, full extract, and extract without volatile oil in a dosedependent response. This assay also showed no effect in the volatile oil group.
On the test of inflammatory nociception, the control animals are expected to show
increased writhes, as there is no drug-induced analgesia to mediate the pain response.
Animals that produce less writhes show more robust analgesic action of the treatment
group that they received. In this assay, a similar pattern of analgesia against chemoinflammatory pain was observed. The isolated THC treatment group showed robust
analgesia, with the 5.0 mg/kg treatment group being the only compound to average 0
writhes for the testing period. The extract without volatile oil and the full extract both
produced significantly less writhes than the vehicle. On the other hand, the volatile oils
showed equivalent average writhes to the vehicle group, suggesting that volatile oils have
no effect on inflammatory nociception. The attenuation of writhing behavior suggests that
the isolated THC, the extract without volatile oils, and the full extract produced robust
analgesia against chemo-inflammatory pain, while the volatile oils (terpenes) did not.
The results of the two thermal nociception assays and the inflammatory
nociception assay revealed that isolated THC produced robust analgesia equivalent to the
whole extract. This observation suggests that THC alone is the responsible constituent for
mediating analgesia and it does not necessitate any other constituent. Furthermore, since
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analgesia was produced by the cannabis products in both thermal and inflammatory
nociception assays, it can be concluded that these products induce analgesia in a spectrum
of pain models and thus, have a broad range of clinical applications.
The use of the hotplate and tail flick test of nociception, specifically, are aimed at
understanding the location where the treatments produce analgesic action. Tail flick test
is a nociceptive assay that is mediated entirely by spinal reflexes. Analgesia produced on
the tail flick apparatus yields evidence of spinal-mediated analgesia (Deuis et al.).
However, the hotplate nociceptive assay engages more organized nociceptive behavior
such as paw flutter, licking, and lifting driven by supraspinal mechanisms. If analgesia is
produced in the hotplate assay, then the pain pathway is supraspinal (Deuis et al.).
Analgesic actions that are produced in one assay, yet not the other help researchers
determine where these drugs have analgesic effects. If there is analgesia on the tail flick
assay, but not the hotplate assay, then pain is mediated on the spinal pathway. If analgesia
is on the hotplate assay, but not the tail flick, then pain is mediated through the
supraspinal pathway (South et al., 1998). In this study, we found that the isolated THC,
extract without volatile oil, and full extract all showed analgesia on both assays. Since
there were robust effects in both tail flick and hotplate assays, it is suggested that these
compounds mediate analgesia through both spinal and supraspinal pathways.
This study is not the first to reveal that cannabinoid extracts produce analgesia. A
study conducted in 1997 documented the role of cannabinoids in mediating analgesia
(Bloom et al. 1999). In this study, albino mice placed equivalent latencies on tail flick test
when injected with (±)-9-nor-9β-hydroxyhexahydrocannabinol (β-HHC) as they did
when treated with morphine (Bloom et al., 1977). Furthermore, this study is not the first
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to suggest that THC alone produces analgesia. Buxbaum et al. showed in 1972 that
isolated THC was comparable in mediating analgesia equivalent to morphine in both rats
and mice using both the hot plate and tail flick tests of thermal nociception (Buxbaum et
al., 1972). More recently, a study by Varvel et al. in 2005 found that in mice, tests of tail
flick latencies, as well as catalepsy and hypothermia revealed Δ9-THC acting via CB1
receptors was the sole constituent responsible for cannabis-mediated analgesia and that
no other known cannabis constituent produced analgesia to this effect (Varvel et al.,
2005). These findings, as well as the findings of this study, lead to the suggestion that
THC should be further explored as a means of treating clinical pain.
Although it is not new evidence that THC alone can mediate analgesia, this study
also found that cannabinoid constituents do not add to the analgesic actions of cannabis
beyond the analgesic actions of isolated THC. While there is evidence that cannabidiol
can have analgesic actions of its own (Notcutt et al., 2004), the extracts used in this study
are from a high THC variety that has only a small amount of CBD. A study to ascertain
the contribution of CBD to the analgesic activity of cannabis needs to be carried out
using extracts of the mixed cannabis variety which contains significant amounts of both
cannabinoids. Also, this study is the first to find that the volatile oils of cannabis
produced no analgesic effect in any of the three assays. This suggested that volatile oils
do not cause alterations in cannabis medicated analgesia. The necessity of this
information is that treatments that complex botanicals with a multitude of chemicals that
are not well understand could have many potential interactions with organ systems that
may lead to an array of side effects. The work herein displays how cannabis extract can
produce robust analgesia without the volatile oils. Indeed, isolated THC by itself may
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prove to be all that is required for producing significant analgesia, thus removing the
potential side effects associated with other constituents in the plant material.
Although THC alone produces robust analgesic action, this study does not
necessarily suggest that other constituents should be completely disregarded. In 2004,
Notcutt et al. found that in a double-blind study of patients with chronic pain from
multiple sclerosis, THC alleviated chronic pain, but a mixture of THC and CBD also
alleviated this pain to the same extent. Further, this study found that patients with chronic
pain placed preference for the THC and CBD mixture (Notcutt et al., 2004). In 1982, a
double-blind study was conducted on healthy subjects who were given either THC, THC
and CBD, diazepam, or placebo. The subjects reported less anxiety, as well as less side
effects, with the THC and CBD treatment than with THC alone (Zuardi et al., 1982). The
study “verified that CBD blocks the anxiety provoked by Δ9-THC, however this effect
also extended to marijuana- like effects and to other subjective alterations induced by
Δ9-THC” (Zuardi et al., 1982). This finding indicates a possible importance of CBD, and
potentially other constituents, on mediating potential side effects that may occur from
using THC alone for treatment of pain. Even if CBD does not add to the overall analgesic
action, it could mitigate the potential for abuse or use of these products for reward, or
recreational, purposes. Further research should be conducted to answer this question.

28

REFERENCES
Bloom, A. S., Dewey, W. L., Harris, L. S., & Brosius, K. K. (1977). 9-nor-9betahydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity:
Comparisons with morphine. Journal of Pharmacology and Experimental
Therapeutics, 200(2), 263.
Broom, S. L., Sufka, K. J., Elsohly, M. A., & Ross, S. A. (2001). Analgesic and
reinforcing properties of Δ9 -THC-hemisuccinate in adjuvant-arthritic rats.
Journal of Cannabis Therapeutics, 1(3-4), 171-182.
Buxbaum, D. M. (1972). Analgesic activity of Δ9 -tetrahydrocannabinol in the rat and
mouse. Psychopharmacologia, 25(3), 275.
Collier, H. O., Dinneen, L. C., Johnson, C. A., & Schneider, C. (1968). The abdominal
constriction response and its suppression by analgesic drugs in the mouse. British
Journal of Pharmacology and Chemotherapy, 32(2), 295–310.
Dias, D. A., Urban, S., & Roessner, U. (2012). A Historical Overview of Natural
Products in Drug Discovery. Metabolites, 2(4), 303–336.
Deuis, J. R., Dvorakova, L. S., & Vetter, I. (2017). Methods Used to Evaluate Pain
Behaviors in Rodents. Frontiers in Molecular Neuroscience, 10, 284.
ElSohly, M. A., & Slade, D. (2005). Chemical constituents of marijuana: The complex
mixture of natural cannabinoids. Life Sciences, 78(5), 539-548.
ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., Galal, A. (2017). Phytochemistry
of Cannabis sativa L., Progress in the Chemistry of Organic Natural Products,
103, 1-36

29

Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional
medicine for drug discovery. Environmental Health Perspectives, 109(Suppl 1),
69–75.
Gourdet, C., Giombi, K. C., Kosa, K., Wiley, J., & Cates, S. (2017). How four U.S. states
are regulating recreational marijuana edibles. The International Journal on Drug
Policy, 43, 83.
Greydanus, D. E., Hawver, E. K., Greydanus, M. M., & Merrick, J. (2013). Marijuana:
Current Concepts. Frontiers in Public Health, 1, 42.
Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017). Cannabis and Pain: A
Clinical Review. Cannabis and Cannabinoid Research, 2(1), 96–104.
Hofmann, M. E., & Frazier, C. J. (2013). Marijuana, endocannabinoids, and epilepsy:
Potential and Challenges for Improved Therapeutic Intervention. Experimental
Neurology, 244, 43-50.
Johanek, L. M., Heitmiller, D. R., Turner, M., Nader, N., Hodges, J., & Simone, D. A.
(2001). Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and
peripheral mechanisms. Pain, 93(3), 303-315.
Lynch, M. E., Young, J., & Clark, A. J. (2006). Clinical note: A case series of patients
using medicinal marihuana for management of chronic pain under the Canadian
marijuana medical access regulations. Journal of Pain and Symptom
Management, 32, 497-501.

30

Mack, A., & Joy, J. E. (2001). Marijuana as medicine?: the science beyond the
controversy. National Academy Press, 77-79.
Mehmedic, Z., Radwan, M., Wanas, A., Khan, I., Cutler, S., & ElSohly, M. (2014). In
vitro binding affinity to human CB1 and CB2 receptors and antimicrobial activity
of volatile oil from high potency Cannabis sativa. Planta Medica, 80(10).
Murthy, V. H. (2016). Ending the opioid epidemic — A call to action. The New England
Journal of Medicine, 375(25), 2413-2415.
Noonan, D. (2015). Marijuana's Medical Future. Scientific American, 312(2), 32-34.
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., Sansom, C.
(2004) Initial experiences with medicinal extracts of cannabis for chronic pain:
results from 34 ‘N of 1’ studies. Anaesthesia. 59(5), 440–452.
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D.
(2007). Sativex successfully treats neuropathic pain characterized by allodynia: A
randomized, double-blind, placebo-controlled clinical trial. Pain, 133(1), 210220.
Paduch, R., Kandefer-Szerszeń, M., Trytek, M., & Fiedurek, J. (2007). Terpenes:
substances useful in human healthcare. Archivum Immunologiae et Therapiae
Experimentalis, 55(5), 315-327.
Pearce, Daniel D., Mitsouras, Katherine, & Irizarry, Kristopher J. (2014). Discriminating
the Effects of Cannabis sativa and Cannabis Indica: A Web Survey of Medical
Cannabis Users. The Journal of Alternative and Complementary Medicine,
20(10), 787-791.
31

Repka, M. A., Munjal, M., ElSohly, M. A., & Ross, S. A. (2006). Temperature Stability
and Bioadhesive Properties of Δ9-Tetrahydrocannabinol Incorporated
Hydroxypropylcellulose Polymer Matrix Systems. Drug Development and
Industrial Pharmacy, 32(1), 21–32.
South, S. M., & Smith, M. T. (1998). Apparent insensitivity of the hotplate latency test
for detection of antinociception following intraperitoneal, intravenous or
intracerebroventricular M6G administration to rats. Journal of Pharmacology and
Experimental Therapeutics, 286(3), 1326.
Suplita, R. L., Farthing, J. N., Gutierrez, T., & Hohmann, A. G. (2005). Inhibition of
fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: Sites
of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla.
Neuropharmacology, 49(8), 1201-1209.
Vale, A. (2007). Cannabis. Medicine, 35(11), 603.
Varvel, S. A. (2005). 9-tetrahydrocannbinol accounts for the antinociceptive,
hypothermic, and cataleptic effects of marijuana in mice. Journal of
Pharmacology and Experimental Therapeutics, 314(1), 329-337.
Walker, J., & Huang, S. M. (2002). Cannabinoid analgesia. Pharmacology &
Therapeutics, 95(2), 127-135.
Wallace, M., Schulteis, G., Atkinson, J.H., Wolfson, T., Lazzaretto, D., Bentley, H.,
Gouaux, B., & Abramson, I. (2007). Dose-dependent effects of smoked cannabis
on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology,
107(5), 785-96.

32

Warf, B. (2014). High Points: An Historical Geography of Cannabis. Geographical
Review, 104(4), 414-438.
Zuardi, A.W., Shirakawa, I., Finkelfarb, E., Karniol, I.G. (1982). Action of Cannabidiol
on the Anxiety and Other Effects Produced by Δ9-THC in Normal Subjects.
Psychopharmacology. 76, 245.

33

